Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $22
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $21 to $22.
Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $21 to $22.